| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 601.85 | 7.3% |
| Total Income | 610.83 | 7.4% |
| Expenditure | 447.85 | 4.4% |
| PBT | 162.98 | 14.8% |
| Net Profit | 121.53 | 14.3% |
| OPM | 28.63% | 1.92pp |
| NPM | 19.90% | 1.61pp |
| EPS | 9.91 | 14.3% |
Alivus Life Sciences Reports Q1FY26 Revenue of Rs. 6,018 Mn, Gross Margins of 55.1%, and EBITDA Margins at 30.1%
01 Aug 2025 · 1 Aug 2025, 07:23 pm
Summary
Alivus Life Sciences Limited, a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, announced its financial results for the quarter ended June 30, 2025. The company reported a revenue of Rs. 6,018 Mn, a growth of 2.2% YoY. The EBITDA was at Rs. 1,813 Mn, a growth of 9.9% YoY. The EBITDA margins were at 30.1%, up 210 bps YoY. The PAT for the quarter stood at Rs. 1,215 Mn and PAT margins were at 20.2%.
Key Highlights
- 1
Revenue from operations for Q1FY26 reached Rs. 6,018 Mn, a growth of 2.2% YoY
- 2
EBITDA was at Rs. 1,813 Mn, a growth of 9.9% YoY
- 3
EBITDA margins were at 30.1%, up 210 bps YoY
- 4
PAT for the quarter stood at Rs. 1,215 Mn and PAT margins were at 20.2%
- 5
The company generated a strong free cash flow of Rs. 1,000 Mn leading to Cash and Cash Equivalents (including short term investments) of Rs. 6,604 Mn as of June 30, 2025
- 6
DMF / CEP filings continue across major markets, taking the total cumulative filings to 569 as on June 30, 2025
- 7
In Q1FY26, five synthetic small molecules were added to the development grid
- 8
The HP API portfolio has 26 APIs in the active grid with nine products validated, three products in advanced stages of development and 14 products under lab development stage
- 9
Solapur — Phase 1 construction work is in progress for 200 KL capacity
Management Comments
Dr. Yasir Rawjee
MD & CEO, Alivus Life Sciences Limited
Our performance this quarter was primarily driven by strong growth in the Non-GPL business, which expanded by 14.5% YoY. Key regions including India (Ex-GPL), Europe, ROW, LATAM, and Japan were major contributors to this growth. We remain confident of achieving high single-digit revenue growth in FY26, with stronger momentum expected in the second half. Margins are projected to remain healthy in the 28-30% range. Our ongoing investments in capacity building and pipeline enrichment form the foundation of our future growth, and we believe these efforts, supported by an increasingly favourable market environment, will help unlock further value.”
Tushar Mistry
CFO, Alivus Life Sciences Limited
Q7F Y26 witnessed robust revenues of Rs. 602 crores, while consistently maintaining our gross margin at ~55% and EBITDA margin around ~30%, well within our guided range. This financial discipline, coupled with a healthy free cash flow of Rs. 100 crores during the quarter, strengthens our debt-free balance sheet and positions us well to achieve the high single-digit growth we anticipate for the full year.
Informational and educational content only. Not investment advice.